Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide

by Business Wire • 2022/09/06 • 0 Comments

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide. This market-leading milestone is a testament to the decades of investment from Glaukos as the corporate founder and pion

← Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

Ray Therapeutics Appoints Dr. Peter Francis as Chief Scientific & Medical Officer and Jenny Holt as SVP, Program Portfolio Management →

Post navigation